

Global Spinal Muscular Atrophy Medicine Market Growth 2025-2031

<https://marketpublishers.com/r/GFBBE29487C2EN.html>

Date: January 2025

Pages: 128

Price: US\$ 3,660.00 (Single User License)

ID: GFBBE29487C2EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Spinal Muscular Atrophy Medicine market size is predicted to grow from US\$ million in 2025 to US\$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the "Spinal Muscular Atrophy Medicine Industry Forecast" looks at past sales and reviews total world Spinal Muscular Atrophy Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Spinal Muscular Atrophy Medicine sales for 2025 through

2031. With Spinal Muscular Atrophy Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Spinal Muscular Atrophy Medicine industry.

This Insight Report provides a comprehensive analysis of the global Spinal Muscular Atrophy Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Spinal Muscular Atrophy Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Spinal Muscular Atrophy Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Spinal Muscular Atrophy Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Spinal Muscular Atrophy Medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Spinal Muscular Atrophy Medicine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

LMI-070

ND-602

NT-1654

Nusinersen

NXD-30001

Others

Segmentation by Application:

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Astellas Pharma Inc.

AveXis, Inc.

Bioblast Pharma Ltd.

Cytokinetics, Inc. 24

F. Hoffmann-La Roche Ltd.

Genethon

Genzyme Corporation

GMP-Orphan SAS

Ionis Pharmaceuticals, Inc.

Longevity Biotech, Inc

Neurodyn Inc.

Neurotune AG

Novartis AG

Sarepta Therapeutics, Inc.

Voyager Therapeutics, Inc.

Vybion, Inc.

WAVE Life Sciences Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Spinal Muscular Atrophy Medicine market?

What factors are driving Spinal Muscular Atrophy Medicine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Spinal Muscular Atrophy Medicine market opportunities vary by end market size?

How does Spinal Muscular Atrophy Medicine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Spinal Muscular Atrophy Medicine by Country/Region, 2020, 2024 & 2031
- 2.2 Spinal Muscular Atrophy Medicine Segment by Type
 - 2.2.1 LMI-070
 - 2.2.2 ND-602
 - 2.2.3 NT-1654
 - 2.2.4 Nusinersen
 - 2.2.5 NXD-30001
 - 2.2.6 Others
- 2.3 Spinal Muscular Atrophy Medicine Sales by Type
 - 2.3.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Type (2020-2025)
- 2.4 Spinal Muscular Atrophy Medicine Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Others
- 2.5 Spinal Muscular Atrophy Medicine Sales by Application

2.5.1 Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2020-2025)

2.5.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2020-2025)

2.5.3 Global Spinal Muscular Atrophy Medicine Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Spinal Muscular Atrophy Medicine Breakdown Data by Company

3.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Company (2020-2025)

3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2020-2025)

3.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Company (2020-2025)

3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Company (2020-2025)

3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2020-2025)

3.3 Global Spinal Muscular Atrophy Medicine Sale Price by Company

3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Spinal Muscular Atrophy Medicine Product Location Distribution

3.4.2 Players Spinal Muscular Atrophy Medicine Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION

4.1 World Historic Spinal Muscular Atrophy Medicine Market Size by Geographic Region (2020-2025)

4.1.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Spinal Muscular Atrophy Medicine Market Size by Country/Region (2020-2025)

4.2.1 Global Spinal Muscular Atrophy Medicine Annual Sales by Country/Region (2020-2025)

4.2.2 Global Spinal Muscular Atrophy Medicine Annual Revenue by Country/Region (2020-2025)

4.3 Americas Spinal Muscular Atrophy Medicine Sales Growth

4.4 APAC Spinal Muscular Atrophy Medicine Sales Growth

4.5 Europe Spinal Muscular Atrophy Medicine Sales Growth

4.6 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Growth

5 AMERICAS

5.1 Americas Spinal Muscular Atrophy Medicine Sales by Country

5.1.1 Americas Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)

5.1.2 Americas Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)

5.2 Americas Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)

5.3 Americas Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Spinal Muscular Atrophy Medicine Sales by Region

6.1.1 APAC Spinal Muscular Atrophy Medicine Sales by Region (2020-2025)

6.1.2 APAC Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025)

6.2 APAC Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)

6.3 APAC Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Spinal Muscular Atrophy Medicine by Country

7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)

7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)

7.2 Europe Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)

7.3 Europe Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Spinal Muscular Atrophy Medicine by Country

8.1.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025)

8.1.2 Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025)

8.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2020-2025)

8.3 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine

10.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine

10.4 Industry Chain Structure of Spinal Muscular Atrophy Medicine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Spinal Muscular Atrophy Medicine Distributors

11.3 Spinal Muscular Atrophy Medicine Customer

12 WORLD FORECAST REVIEW FOR SPINAL MUSCULAR ATROPHY MEDICINE BY GEOGRAPHIC REGION

12.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region

12.1.1 Global Spinal Muscular Atrophy Medicine Forecast by Region (2026-2031)

12.1.2 Global Spinal Muscular Atrophy Medicine Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Spinal Muscular Atrophy Medicine Forecast by Type (2026-2031)

12.7 Global Spinal Muscular Atrophy Medicine Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Astellas Pharma Inc.

13.1.1 Astellas Pharma Inc. Company Information

13.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Astellas Pharma Inc. Main Business Overview

13.1.5 Astellas Pharma Inc. Latest Developments

13.2 AveXis, Inc.

13.2.1 AveXis, Inc. Company Information

13.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and

Gross Margin (2020-2025)

13.2.4 AveXis, Inc. Main Business Overview

13.2.5 AveXis, Inc. Latest Developments

13.3 Bioblast Pharma Ltd.

13.3.1 Bioblast Pharma Ltd. Company Information

13.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.3.4 Bioblast Pharma Ltd. Main Business Overview

13.3.5 Bioblast Pharma Ltd. Latest Developments

13.4 Cytokinetics, Inc.

13.4.1 Cytokinetics, Inc. 24 Company Information

13.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.4.4 Cytokinetics, Inc. 24 Main Business Overview

13.4.5 Cytokinetics, Inc. 24 Latest Developments

13.5 F. Hoffmann-La Roche Ltd.

13.5.1 F. Hoffmann-La Roche Ltd. Company Information

13.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.5.4 F. Hoffmann-La Roche Ltd. Main Business Overview

13.5.5 F. Hoffmann-La Roche Ltd. Latest Developments

13.6 Genethon

13.6.1 Genethon Company Information

13.6.2 Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 Genethon Main Business Overview

13.6.5 Genethon Latest Developments

13.7 Genzyme Corporation

13.7.1 Genzyme Corporation Company Information

13.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Genzyme Corporation Main Business Overview

13.7.5 Genzyme Corporation Latest Developments

13.8 GMP-Orphan SAS

13.8.1 GMP-Orphan SAS Company Information

13.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 GMP-Orphan SAS Main Business Overview

13.8.5 GMP-Orphan SAS Latest Developments

13.9 Ionis Pharmaceuticals, Inc.

13.9.1 Ionis Pharmaceuticals, Inc. Company Information

13.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Ionis Pharmaceuticals, Inc. Main Business Overview

13.9.5 Ionis Pharmaceuticals, Inc. Latest Developments

13.10 Longevity Biotech, Inc

13.10.1 Longevity Biotech, Inc Company Information

13.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Longevity Biotech, Inc Main Business Overview

13.10.5 Longevity Biotech, Inc Latest Developments

13.11 Neurodyn Inc.

13.11.1 Neurodyn Inc. Company Information

13.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.11.4 Neurodyn Inc. Main Business Overview

13.11.5 Neurodyn Inc. Latest Developments

13.12 Neurotune AG

13.12.1 Neurotune AG Company Information

13.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolios and

Specifications

13.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.12.4 Neurotune AG Main Business Overview

13.12.5 Neurotune AG Latest Developments

13.13 Novartis AG

13.13.1 Novartis AG Company Information

13.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.13.4 Novartis AG Main Business Overview

13.13.5 Novartis AG Latest Developments

13.14 Sarepta Therapeutics, Inc.

13.14.1 Sarepta Therapeutics, Inc. Company Information

13.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.14.4 Sarepta Therapeutics, Inc. Main Business Overview

13.14.5 Sarepta Therapeutics, Inc. Latest Developments

13.15 Voyager Therapeutics, Inc.

13.15.1 Voyager Therapeutics, Inc. Company Information

13.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.15.4 Voyager Therapeutics, Inc. Main Business Overview

13.15.5 Voyager Therapeutics, Inc. Latest Developments

13.16 Vybion, Inc.

13.16.1 Vybion, Inc. Company Information

13.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.16.4 Vybion, Inc. Main Business Overview

13.16.5 Vybion, Inc. Latest Developments

13.17 WAVE Life Sciences Ltd.

13.17.1 WAVE Life Sciences Ltd. Company Information

13.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

13.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue, Price and Gross Margin (2020-2025)

13.17.4 WAVE Life Sciences Ltd. Main Business Overview

13.17.5 WAVE Life Sciences Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Spinal Muscular Atrophy Medicine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of LMI-070

Table 4. Major Players of ND-602

Table 5. Major Players of NT-1654

Table 6. Major Players of Nusinersen

Table 7. Major Players of NXD-30001

Table 8. Major Players of Others

Table 9. Global Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)

Table 10. Global Spinal Muscular Atrophy Medicine Sales Market Share byType (2020-2025)

Table 11. Global Spinal Muscular Atrophy Medicine Revenue byType (2020-2025) & (\$ million)

Table 12. Global Spinal Muscular Atrophy Medicine Revenue Market Share byType (2020-2025)

Table 13. Global Spinal Muscular Atrophy Medicine Sale Price byType (2020-2025) & (USD/Pcs)

Table 14. Global Spinal Muscular Atrophy Medicine Sale by Application (2020-2025) & (K Pcs)

Table 15. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2020-2025)

Table 16. Global Spinal Muscular Atrophy Medicine Revenue by Application (2020-2025) & (\$ million)

Table 17. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2020-2025)

Table 18. Global Spinal Muscular Atrophy Medicine Sale Price by Application (2020-2025) & (USD/Pcs)

Table 19. Global Spinal Muscular Atrophy Medicine Sales by Company (2020-2025) & (K Pcs)

Table 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company (2020-2025)

Table 21. Global Spinal Muscular Atrophy Medicine Revenue by Company (2020-2025) & (\$ millions)

Table 22. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2020-2025)

Table 23. Global Spinal Muscular Atrophy Medicine Sale Price by Company (2020-2025) & (USD/Pcs)

Table 24. Key Manufacturers Spinal Muscular Atrophy Medicine Producing Area Distribution and Sales Area

Table 25. Players Spinal Muscular Atrophy Medicine Products Offered

Table 26. Spinal Muscular Atrophy Medicine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 27. New Products and Potential Entrants

Table 28. Market M&A Activity & Strategy

Table 29. Global Spinal Muscular Atrophy Medicine Sales by Geographic Region (2020-2025) & (K Pcs)

Table 30. Global Spinal Muscular Atrophy Medicine Sales Market Share Geographic Region (2020-2025)

Table 31. Global Spinal Muscular Atrophy Medicine Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region (2020-2025)

Table 33. Global Spinal Muscular Atrophy Medicine Sales by Country/Region (2020-2025) & (K Pcs)

Table 34. Global Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2020-2025)

Table 35. Global Spinal Muscular Atrophy Medicine Revenue by Country/Region (2020-2025) & (\$ millions)

Table 36. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Country/Region (2020-2025)

Table 37. Americas Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)

Table 38. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2025)

Table 39. Americas Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & (\$ millions)
Table 40. Americas Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 41. Americas Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Table 44. APAC Spinal Muscular Atrophy Medicine Revenue by Region (2020-2025) & (\$ millions)
Table 45. APAC Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 46. APAC Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2020-2025) & (\$ millions)
Table 49. Europe Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 50. Europe Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Spinal Muscular Atrophy Medicine Sales byType (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Spinal Muscular Atrophy Medicine
Table 56. Key Market Challenges & Risks of Spinal Muscular Atrophy Medicine
Table 57. Key IndustryTrends of Spinal Muscular Atrophy Medicine
Table 58. Spinal Muscular Atrophy Medicine Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Spinal Muscular Atrophy Medicine Distributors List

Table 61. Spinal Muscular Atrophy Medicine Customer List
Table 62. Global Spinal Muscular Atrophy Medicine SalesForecast by Region (2026-2031) & (K Pcs)
Table 63. Global Spinal Muscular Atrophy Medicine RevenueForecast by Region (2026-2031) & (\$ millions)
Table 64. Americas Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Spinal Muscular Atrophy Medicine Annual RevenueForecast by Country (2026-2031) & (\$ millions)
Table 66. APAC Spinal Muscular Atrophy Medicine SalesForecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Spinal Muscular Atrophy Medicine Annual RevenueForecast by Region (2026-2031) & (\$ millions)
Table 68. Europe Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Spinal Muscular Atrophy Medicine RevenueForecast by Country (2026-2031) & (\$ millions)
Table 70. Middle East & Africa Spinal Muscular Atrophy Medicine SalesForecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Spinal Muscular Atrophy Medicine RevenueForecast by Country (2026-2031) & (\$ millions)
Table 72. Global Spinal Muscular Atrophy Medicine SalesForecast byType (2026-2031) & (K Pcs)
Table 73. Global Spinal Muscular Atrophy Medicine RevenueForecast byType (2026-2031) & (\$ millions)
Table 74. Global Spinal Muscular Atrophy Medicine SalesForecast by Application (2026-2031) & (K Pcs)
Table 75. Global Spinal Muscular Atrophy Medicine RevenueForecast by Application (2026-2031) & (\$ millions)
Table 76. Astellas Pharma Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors
Table 77. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications
Table 78. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. Astellas Pharma Inc. Main Business
Table 80. Astellas Pharma Inc. Latest Developments
Table 81. AveXis, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 82. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 83. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 84. AveXis, Inc. Main Business

Table 85. AveXis, Inc. Latest Developments

Table 86. Bioblast Pharma Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 87. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 88. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 89. Bioblast Pharma Ltd. Main Business

Table 90. Bioblast Pharma Ltd. Latest Developments

Table 91. Cytokinetics, Inc. 24 Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 92. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 93. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 94. Cytokinetics, Inc. 24 Main Business

Table 95. Cytokinetics, Inc. 24 Latest Developments

Table 96.F. Hoffmann-La Roche Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 97.F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 98.F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 99.F. Hoffmann-La Roche Ltd. Main Business

Table 100.F. Hoffmann-La Roche Ltd. Latest Developments

Table 101. Genethon Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 102. Genethon Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 103. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 104. Genethon Main Business

Table 105. Genethon Latest Developments

Table 106. Genzyme Corporation Basic Information, Spinal Muscular Atrophy Medicine

Manufacturing Base, Sales Area and Its Competitors

Table 107. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 108. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 109. Genzyme Corporation Main Business

Table 110. Genzyme Corporation Latest Developments

Table 111. GMP-Orphan SAS Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 112. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 113. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 114. GMP-Orphan SAS Main Business

Table 115. GMP-Orphan SAS Latest Developments

Table 116. Ionis Pharmaceuticals, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 117. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 118. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 119. Ionis Pharmaceuticals, Inc. Main Business

Table 120. Ionis Pharmaceuticals, Inc. Latest Developments

Table 121. Longevity Biotech, Inc Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 122. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 123. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 124. Longevity Biotech, Inc Main Business

Table 125. Longevity Biotech, Inc Latest Developments

Table 126. Neurodyn Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 127. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 128. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 129. Neurodyn Inc. Main Business

Table 130. Neurodyn Inc. Latest Developments

Table 131. Neurotune AG Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 132. Neurotune AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 133. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 134. Neurotune AG Main Business

Table 135. Neurotune AG Latest Developments

Table 136. Novartis AG Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 137. Novartis AG Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 138. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 139. Novartis AG Main Business

Table 140. Novartis AG Latest Developments

Table 141. SareptaTherapeutics, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 142. SareptaTherapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 143. SareptaTherapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 144. SareptaTherapeutics, Inc. Main Business

Table 145. SareptaTherapeutics, Inc. Latest Developments

Table 146. VoyagerTherapeutics, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 147. VoyagerTherapeutics, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 148. VoyagerTherapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 149. VoyagerTherapeutics, Inc. Main Business

Table 150. VoyagerTherapeutics, Inc. Latest Developments

Table 151. Vybion, Inc. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 152. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 153. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 154. Vybion, Inc. Main Business

Table 155. Vybion, Inc. Latest Developments

Table 156. WAVE Life Sciences Ltd. Basic Information, Spinal Muscular Atrophy Medicine Manufacturing Base, Sales Area and Its Competitors

Table 157. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Portfolios and Specifications

Table 158. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 159. WAVE Life Sciences Ltd. Main Business

Table 160. WAVE Life Sciences Ltd. Latest Developments

LIST OFFIGURES

Figure 1. Picture of Spinal Muscular Atrophy Medicine

Figure 2. Spinal Muscular Atrophy Medicine Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Spinal Muscular Atrophy Medicine Sales Growth Rate 2020-2031 (K Pcs)

Figure 7. Global Spinal Muscular Atrophy Medicine Revenue Growth Rate 2020-2031 (\$ millions)

Figure 8. Spinal Muscular Atrophy Medicine Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 9. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2024)

Figure 10. Spinal Muscular Atrophy Medicine Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 11. Product Picture of LMI-070

Figure 12. Product Picture of ND-602

Figure 13. Product Picture of NT-1654

Figure 14. Product Picture of Nusinersen

Figure 15. Product Picture of NXD-30001

Figure 16. Product Picture of Others

Figure 17. Global Spinal Muscular Atrophy Medicine Sales Market Share byType in 2025

Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Market Share byType (2020-2025)

Figure 19. Spinal Muscular Atrophy Medicine Consumed in Hospital

Figure 20. Global Spinal Muscular Atrophy Medicine Market: Hospital (2020-2025) & (K Pcs)

Figure 21. Spinal Muscular Atrophy Medicine Consumed in Clinic

Figure 22. Global Spinal Muscular Atrophy Medicine Market: Clinic (2020-2025) & (K Pcs)

Figure 23. Spinal Muscular Atrophy Medicine Consumed in Others

Figure 24. Global Spinal Muscular Atrophy Medicine Market: Others (2020-2025) & (K Pcs)

Figure 25. Global Spinal Muscular Atrophy Medicine Sale Market Share by Application (2024)

Figure 26. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application in 2025

Figure 27. Spinal Muscular Atrophy Medicine Sales by Company in 2025 (K Pcs)

Figure 28. Global Spinal Muscular Atrophy Medicine Sales Market Share by Company in 2025

Figure 29. Spinal Muscular Atrophy Medicine Revenue by Company in 2025 (\$ millions)

Figure 30. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company in 2025

Figure 31. Global Spinal Muscular Atrophy Medicine Sales Market Share by Geographic Region (2020-2025)

Figure 32. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Geographic Region in 2025

Figure 33. Americas Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)

Figure 34. Americas Spinal Muscular Atrophy Medicine Revenue 2020-2025 (\$ millions)

Figure 35. APAC Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)

Figure 36. APAC Spinal Muscular Atrophy Medicine Revenue 2020-2025 (\$ millions)

Figure 37. Europe Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)

Figure 38. Europe Spinal Muscular Atrophy Medicine Revenue 2020-2025 (\$ millions)

Figure 39. Middle East & Africa Spinal Muscular Atrophy Medicine Sales 2020-2025 (K Pcs)

Figure 40. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue 2020-2025 (\$ millions)

Figure 41. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025

Figure 42. Americas Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)

Figure 43. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)

Figure 44. Americas Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)

Figure 45. United States Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 46. Canada Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 47. Mexico Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 48. Brazil Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 49. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2025

Figure 50. APAC Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)

Figure 51. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)

Figure 52. APAC Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)

Figure 53. China Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 54. Japan Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 55. South Korea Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 56. Southeast Asia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 57. India Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 58. Australia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 59. ChinaTaiwan Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 60. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2025

Figure 61. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2020-2025)

Figure 62. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)

Figure 63. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Application

(2020-2025)

Figure 64. Germany Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 65. France Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 66. UK Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 67. Italy Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 68. Russia Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 69. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2020-2025)

Figure 70. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)

Figure 71. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)

Figure 72. Egypt Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 73. South Africa Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 74. Israel Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 75. Turkey Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 76. GCC Countries Spinal Muscular Atrophy Medicine Revenue Growth 2020-2025 (\$ millions)

Figure 77. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2025

Figure 78. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine

Figure 79. Industry Chain Structure of Spinal Muscular Atrophy Medicine

Figure 80. Channels of Distribution

Figure 81. Global Spinal Muscular Atrophy Medicine Sales Market Forecast by Region (2026-2031)

Figure 82. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Region (2026-2031)

Figure 83. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2026-2031)

Figure 84. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast

byType (2026-2031)

Figure 85. Global Spinal Muscular Atrophy Medicine Sales Market ShareForecast by Application (2026-2031)

Figure 86. Global Spinal Muscular Atrophy Medicine Revenue Market ShareForecast by Application (2026-2031)

I would like to order

Product name: Global Spinal Muscular Atrophy Medicine Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/GFBBE29487C2EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFBBE29487C2EN.html>